Page last updated: 2024-12-11

dehydroergosterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dehydroergosterol : A phytosterol consiting of ergostane having double bonds at the 5,6-, 7,8- 9,11- and 22,23-positions as well as a 3beta-hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6436660
CHEBI ID64762
MeSH IDM0056791

Synonyms (29)

Synonym
ergosta-5,7,9(11),22-tetraen-3beta-ol, ~96% (hplc)
dehydroergosterol
(3s,10s,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,12,14,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-3-ol
ergosta-5,7,9(11),22-tetraen-3beta-ol
LMST01031023
CHEBI:64762
(3beta,22e)-ergosta-5,7,9(11),22-tetraen-3-ol
(22e)-ergosta-5,7,9(11),22-tetraen-3beta-ol
unii-123r6kjq51
123r6kjq51 ,
516-85-8
delta(5,7,9(11)22)-ergostatetraen-3-ol
ergosta-5,7,9(11),22-tetraen-3-ol, (3beta,22e)-
(22e,24r)-ergosta-5,7,9(11),22-tetraen-3.beta.-ol
9(11)-dehydroergosterol
ergosta-5,7,9(11),22-tetraen-3-ol, (3.beta.,22e)-
(3.beta.,22e)-ergosta-5,7,9(11),22-tetraen-3-ol
dehydroergosterol, (+)-
dehydroergosterol [mi]
QSVJYFLQYMVBDR-CMNOFMQQSA-N
NCGC00485372-01
Q27133411
ergosta-5,7,9(11),22-tetraen-3b-ol
(3s,10s,13r,14r,17r)-17-((2r,5r,e)-5,6-dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,10,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
DTXSID601026574
AS-82976
CS-0067723
AKOS040756082
HY-118667

Research Excerpts

Overview

14-dehydroergosterol is an ergosterol analogue with a conjugated double bond. It has been employed for direct observation of intracellular sterol transport by UV microscopy.

ExcerptReferenceRelevance
"14-dehydroergosterol is an ergosterol analogue with a conjugated double bond, but the activity of 14-dehydroergosterol is much higher than that of ergosterol."( Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells.
Ano, Y; Fujiwara, D; Ikado, K; Koizumi, H; Shindo, K, 2017
)
1.29
"Dehydroergosterol (DHE) is an intrinsically fluorescent sterol with absorption/emission in the ultraviolet (UV) region and biophysical properties similar to those of cholesterol. "( Potential of ultraviolet wide-field imaging and multiphoton microscopy for analysis of dehydroergosterol in cellular membranes.
Bagatolli, L; Brewer, JR; Sage, D; Wüstner, D, 2011
)
2.03
"Dehydroergosterol is a natural yeast sterol which has recently been employed for direct observation of intracellular sterol transport by UV microscopy. "( Improved visualization and quantitative analysis of fluorescent membrane sterol in polarized hepatic cells.
Wüstner, D, 2005
)
1.77

Treatment

ExcerptReferenceRelevance
"14-dehydroergosterol-treated human DCs induced from PBMCs also showed a tolerogenic phenotype."( Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells.
Ano, Y; Fujiwara, D; Ikado, K; Koizumi, H; Shindo, K, 2017
)
1.29

Toxicity

ExcerptReferenceRelevance
"We have developed a fluorescence method to examine how membrane sterol lateral organization affects the potency of antioxidants, and used this information to evaluate possible adverse effects of lipid-soluble antioxidants seen in recent clinical studies."( Sterol superlattice affects antioxidant potency and can be used to assess adverse effects of antioxidants.
Chong, PL; Olsher, M, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
biomarkerA substance used as an indicator of a biological state.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
ergostanoid
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
phytosterolsSterols similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (15.15)18.7374
1990's32 (24.24)18.2507
2000's51 (38.64)29.6817
2010's27 (20.45)24.3611
2020's2 (1.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.02 (24.57)
Research Supply Index4.90 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (3.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other128 (96.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]